Kvantify Raises €7M in Second Close of Funding Round

Why It Matters

The infusion of capital and academic collaboration speeds the commercialization of quantum‑enhanced drug discovery, potentially shortening R&D cycles and lowering costs for the pharmaceutical industry.

Key Takeaways

• €7M round fuels hybrid quantum drug discovery software
• Qrunch platform enables chemists to run quantum‑classical simulations
• ODAQS project applies reinforcement learning to optimize quantum code
• Kvantify leverages Denmark’s Gefion supercomputer for quantum simulations
• FAST‑VQE demonstrated on ~50‑qubit systems, showing scalability

Pulse Analysis

Hybrid quantum‑classical workflows are emerging as the most pragmatic path for applying quantum computing to drug discovery, and Kvantify is positioning itself at the forefront. By marrying conventional computational chemistry with quantum algorithms such as FAST‑VQE and BEAST‑VQE, its Qrunch platform abstracts the complexity of quantum programming, enabling chemists to focus on molecular design. This approach reduces the need for deep quantum expertise and makes it feasible for pharmaceutical labs to experiment with quantum‑accelerated simulations today, even on noisy intermediate‑scale quantum (NISQ) hardware.

The recent €7 million financing round underscores investor confidence in Kvantify’s software‑first strategy. Coupled with a $10.8 million seed round and European Innovation Council backing, the capital will fund further development, scaling, and commercialization of the Qrunch suite. Parallelly, the ODAQS collaboration with Aarhus and Aalborg universities introduces reinforcement‑learning techniques to automatically generate efficient quantum programs, addressing one of the biggest bottlenecks: resource‑intensive quantum circuit optimization. This academic partnership not only accelerates algorithmic innovation but also creates a pipeline of talent and IP that strengthens Kvantify’s market position.

Leveraging Denmark’s national AI supercomputer, Gefion, Kvantify can simulate quantum systems far beyond the capabilities of existing quantum processors. These large‑scale classical simulations allow rapid testing of new algorithms, validation of chemical models, and preparation for future hardware upgrades. As quantum processors scale toward higher qubit counts, the company’s hybrid stack—bolstered by advanced software tooling and robust classical support—will be critical for delivering actionable insights in pharmaceutical research, potentially compressing discovery timelines and reducing development costs.

Deal Summary

Danish quantum software company Kvantify completed the second close of a €7 million funding round earlier this month to advance its hybrid quantum‑classical drug discovery platform. The financing follows a $10.8 million seed round in 2024 and will support further development and commercialization of its quantum chemistry software stack.